Safety of Irinotecan-based chemotherapy as second-line treatment in extrapulmonary poorly differentiated neuroendocrine carcinomas (NECs)

#3167

Introduction: Owing to their low incidence, little evidence is available on the proper treatment of Neuroendocrine Carcinomas (NECs), a subgroup of tumors with scarce prognosis. Platinum plus Etoposide have been validated as first-line therapy since the 1991, while there is no consensus regarding further-lines treatment. Irinotecan (IRI)-based chemotherapy have shown promising results in second-line setting but data on safety are poor.

Aim(s): The aim of our study was to evaluate safety and feasibility of IRI-based chemotherapy in extrapulmonary NECs in a real-life setting.

Materials and methods: Patients with a diagnosis of NEC treated at Modena Cancer Centre with an IRI-based chemotherapy (FOLFIRI, mFOLFIRI plus or minus bevacizumab, XELIRI) after failure of Platinum plus Etoposide first-line treatment were included in our analysis. Adverse events (AE) were evaluated using Common Terminology Criteria for Adverse Events version 5.0.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Bardasi C

Authors: Bardasi C, Spallanzani A, Luppi G, Bertolini F, Fontana A,

Keywords: neuroendocrine carcinoma, Irinotecan, safety, second-line treatment, chemotherapy, NEC, adverse events,